Remedy: Strong Cash flows from Development Fees

Research Note

2022-05-13

10:34

Redeye comments on Remedy’s Q1 business review. Revenue was EUR 1.3 million above our estimate, EUR 12.7 million versus EUR 11.4 million. The cost base was roughly in line, which resulted in an EBIT somewhat above our estimate.

TO

VL

Tomas Otterbeck

Viktor Lindström

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.